128 active not recruiting. 128 Phase 1, 47 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 128 | Active not recruiting 128 |
| Phase 2 | 47 | Active not recruiting 47 |
Follow Vascular Diseases: new trials by email Literature Review of Vascular Diseases trials Research Report on Vascular Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis EA5 - Antiphospholipid Syndrome (APS), Thrombosis | Phase 1 | Active not recruiting | Shanghai Lanyi Therapeutics Co., Ltd. | 12 | 2026-05-25 | 2026-06-08 |
| Study of IBI3016 in People With Mild or Moderate Hypertension Patients IBI3016, Placebo - Hypertension | Phase 1 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 30 | 2026-05-08 | 2026-09-23 |
| Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) Anisodine Hydrobromide - Acute Ischemic Stroke | Phase 1 | Active not recruiting | Capital Medical University | 92 | 2026-04-28 | 2026-08-24 |
| CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis CC-97540, Lymphodepletion Chemotherapy - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 / Phase 2 | Active not recruiting | Marcela V. Maus, M.D.,Ph.D. | 12 | 2026-03-30 | 2026-09-10 |
| A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma RO7875913, Placebo, Cevostamab - Healthy Volunteers, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 240 | 2026-03-11 | 2026-09-30 |
| Study of BMS-986453 in Newly Diagnosed Multiple Myeloma BMS-986453 - Multiple Myeloma | Phase 1 | Active not recruiting | Susan Bal | 25 | 2026-02-09 | 2026-10-09 |
| A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia BHV-7000, Placebo - Familial Erythromelalgia | Phase 1 | Active not recruiting | Biohaven Therapeutics Ltd. | 5 | 2026-01-15 | 2026-10-29 |
| Air-Dried Human Amniotic Membrane Terminally Sterilized by Gamma Irradiation for Multidisciplinary Clinical Application Air-Dried Human Amniotic Membrane (AD-hAM) - Diabetic Foot Ulcer (DFU), Ocular Disorder | Phase 1 | Active not recruiting | Libyan Center for Biotechnology Research | 2 | 2025-11-01 | 2026-06-29 |
| A Phase Ⅰ b Clinical Study of ART101 Injection ART101 injection - Hypertension (HTN) | Phase 1 | Active not recruiting | Arnatar Therapeutics, Inc. | 16 | 2025-10-27 | 2026-05-29 |
| A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma Cevostamab, Tocilizumab - Multiple Myeloma | Phase 1 | Active not recruiting | Hoffmann-La Roche | 20 | 2025-05-13 | 2026-08-28 |
| Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant Recombinant glycosylated human interleukin-7, Melphalan, Autologous hematopoietic cell transplant - Multiple Myeloma | Phase 1 | Active not recruiting | Washington University School of Medicine | 30 | 2025-04-04 | 2026-09-01 |
| Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI Atibuclimab (IC14), 20 mg/kg intravenously, once, Placebo, 150 mL intravenously, once - STEMI, STEMI (ST Elevation MI) | Phase 1 / Phase 2 | Active not recruiting | Implicit Bioscience | 10 | 2025-02-06 | 2026-03-27 |
| A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma JNJ-87562761 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 17 | 2024-12-19 | 2026-11-03 |
| Use of Extracellular Vesicles (EV) for Diabetic Foot Ulcers Extracellular micro vesicles (EV) - Diabetic Foot Ulcer | Phase 1 | Active not recruiting | University of Jordan | 10 | 2024-12-01 | 2025-04-16 |
| A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) ALN-6400, Placebo - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Active not recruiting | Alnylam Pharmaceuticals | 89 | 2024-11-07 | 2026-10-15 |
| The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) Telitacicept 160mg, Prednisone (and methylprednisolone), Cyclophosphamide - Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) | Phase 1 / Phase 2 | Active not recruiting | Renmin Hospital of Wuhan University | 15 | 2024-10-10 | 2024-10-24 |
| A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma CLN-619 - Multiple Myeloma | Phase 1 | Active not recruiting | Cullinan Therapeutics Inc. | 30 | 2024-09-03 | 2025-09-18 |
| CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 KYV-101, Cyclophosphamide, Fludarabine - Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis | Phase 1 | Active not recruiting | David Porter | 24 | 2024-08-05 | 2026-09-21 |
| Dose Optimization of Caffeine for HIE Caffeine citrate 20 mg/kg, Caffeine citrate 30 mg/kg - Hypoxic-Ischemic Encephalopathy | Phase 1 | Active not recruiting | University of North Carolina, Chapel Hill | 16 | 2024-07-26 | 2026-08-14 |
| Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig - Multiple Myeloma | Phase 1 | Active not recruiting | AbbVie | 60 | 2024-06-17 | 2026-03-27 |
Showing 20 of 128. Sign in to see all of them.
Multiple Myeloma (78) · Recurrence (15) · Lymphoma, Non-Hodgkin (9) · Waldenstrom Macroglobulinemia (9) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Lymphoma, Follicular (8) · Lymphoma, Mantle-Cell (8) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Large B-Cell, Diffuse (6) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (5) · Diabetic Foot (5) · Hypertension (5) · Neoplasms, Plasma Cell (5) · Hematologic Neoplasms (4) · Ischemic Stroke (4)
Cardiovascular Diseases (126) · Immune System Diseases (97) · Hemic and Lymphatic Diseases (89) · Hematologic Diseases (88) · Hemorrhagic Disorders (87) · Hemostatic Disorders (87) · Lymphoproliferative Disorders (86) · Blood Protein Disorders (85) · Immunoproliferative Disorders (85) · Neoplasms by Histologic Type (85) · Paraproteinemias (85) · Neoplasms (82) · Neoplasms, Plasma Cell (81) · Pathological Conditions, Signs and Symptoms (34)
Dexamethasone (23) · Lenalidomide (13) · belantamab mafodotin (12) · pomalidomide (11) · Calcium Dobesilate (10) · Cyclophosphamide (10) · daratumumab (10) · carfilzomib (9) · Bortezomib (7) · fludarabine (7) · auricularum (6) · dexamethasone 21-phosphate (6) · dexamethasone acetate (6) · nirogacestat (6) · fludarabine phosphate (4)
GlaxoSmithKline (8) · AbbVie (6) · Janssen Research & Development, LLC (6) · Memorial Sloan Kettering Cancer Center (6) · Mayo Clinic (4) · Massachusetts General Hospital (3) · University of Pennsylvania (3) · ADARx Pharmaceuticals, Inc. (2) · Baylor College of Medicine (2) · Celgene (2) · Genentech, Inc. (2) · Hoffmann-La Roche (2) · Marcela V. Maus, M.D.,Ph.D. (2) · Pfizer (2) · Poseida Therapeutics, Inc. (2)
United States (100) · Australia (22) · Spain (21) · France (20) · Canada (17) · Germany (16) · Israel (12) · South Korea (12) · Netherlands (10) · China (9) · Italy (9) · Greece (8) · Japan (8) · United Kingdom (8) · Poland (7)
Sham Mailankody, MBBS (2) · Abdullah M Khan, MBBS, MSc (1) · Alan H Cohen, MD (1) · Alexander Reyzelman, MD (1) · Alfred Garfall, MD (1) · Alisha Oropallo, MD (1) · Andrew J. Yee, MD (1) · Antonio Abbate, MD, PhD (1)
PMID 34515338, PMID 10231466, PMID 12219027, PMID 12234307, PMID 12389082, PMID 15251365, PMID 15358759, PMID 15618244, PMID 15670785, PMID 15698835, PMID 17336333, PMID 1963650, PMID 19638737, PMID 20385792, PMID 21274961, PMID 21398592, PMID 21658244, PMID 21691090, PMID 22572084, PMID 23417027, PMID 23552495, PMID 24191286, PMID 25355819, PMID 25491299, PMID 25824111, PMID 27088798, PMID 27118452, PMID 27270177, PMID 2850395, PMID 3018561, PMID 32956453, PMID 33682447, PMID 33730360, PMID 33785483, PMID 34398099, PMID 34398557, PMID 34729682, PMID 35303007, PMID 35468618, PMID 35737298, PMID 36029527, PMID 36170501, PMID 36209764, PMID 37173224, PMID 37930156, PMID 38118406, PMID 38270219, PMID 38294975, PMID 38776914, PMID 38912856
2023 (18), 2019 (4), 2016 (1), 2025 (1), DP2HD101400 (1), K23HD111623 (1), P30CA014089 (1), P30CA022453 (1), P30CA138292 (1), P50CA107399 (1), R01HL104032 (1), UM1CA186686 (1)